PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 11, 2004, Pages 2847-2851

  Abbott, Belinda M ^a   Thompson, Philip E ^b,c  

^a MONASH UNIVERSITY   (Australia)

^b BOX HILL HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

2 Morpholinochromone; Inhibitor; LY294002; PDE2; Phosphodiesterase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CELL ENZYME; CHROMONE DERIVATIVE; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; ENZYME INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE;

ARTICLE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; EVALUATION; HUMAN; IN VITRO STUDY; THROMBOCYTE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; BLOOD PLATELETS; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MORPHOLINES; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2342452006     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.03.043     Document Type: Article

References (25)

1. Manganiello V.C., Degerman E. Thromb. Haemost. 82:1999;407
2. Beavo J.A., Brunton L.L. Nature Rev. Mol. Cell Biol. 3:2002;710
3. Perry M.J., Higgs G.A. Curr. Opin. Chem. Biol. 2:1998;472
4. Mehats C., Anderson C.B., Filopanti M., Jin S.-L.C., Conti M. Trends Endocrin. Metabol. 13:2002;29
5. Podzuweit T., Nennstiel P., Müller A. Cell. Signal. 7:1995;733
6. Thompson W.J., Piazza G.A., Li H., Liu L., Fetter J., Zhu B., Speri G., Ahnen D., Pamukcu R. Cancer Res. 60:2000;3338
7. Niewöhner, U.; Schauss, D., Hendrix, M.; König, G.; Böss, F.-G.; van der Staay, F.-J.; Schreiber, R.; Schlemmer, K.-H.; Grosser, R. WO Patent 050078, 2002
8. Whitehead, C. M.; Earle, K. A.; Alila, H. W.; Thompson, W. J. WO Patent 017999, 2003
9. Vlahos C.J., Matter W.F., Hui K.Y., Brown R.F. J. Biol. Chem. 269:1994;5241
10. Benjamin C.W., Lin A.H., Morris J., Wishka D.G., Gorman R.R. J. Pharmacol. Exp. Ther. 265:1993;457
11. Dickinson N., Jang E.K., Haslam R.J. Biochem. J. 323:1997;371
12. Abbott B., Thompson P. Aust. J. Chem. 56:2003;1099-1106
13. Morris J., Wishka D.G., Lin A.H., Humphrey W.R., Wiltse A.L., Gammill R.B., Judge T.M., Bisaha S.N., Olds N.L., Jacob C.S., Bergh C.L., Cudahy M.M., Williams D.J., Nishizawa E.E., Thomas E.W., Gorman R.R., Benjamin C.W., Shebuski R.J. J. Med. Chem. 36:1993;2026
14. Gammill, R. B.; Judge, T. M.; Morris, J. WO Patent 006921, 1990
15. + was seen)
16. Horie T., Kobayashi T., Kawamura Y., Yoshida I., Tominaga H., Yamashita K. Bull. Chem. Soc. Jpn. 68:1995;2033
17. 50 is defined as the concentration of inhibitor where 50% of the AMP production has been inhibited as compared to the DMSO control
18. Sudo T., Tachibana K., Toga K., Tochozawa S., Inoue Y., Kimura Y., Hiroyoshi H. Biochem. Pharmacol. 59:2000;347
19. Izzard R.A., Jackson S.P., Smith G.C.M. Cancer Res. 59:1999;2581
20. Davies S.P., Reddy H., Caivano M., Cohen P. Biochem. J. 351:2000;91
21. Pasapera Limon A.M., Herrera-Munoz J., Gutierrez-Sagal R., Ulloa-Aguirre A. Mol. Cell. Endocrinol. 200:2003;199
22. Kuppusamy U.R., Das N.P. Biochem. Pharmacol. 44:1992;1307
23. Matter W.F., Brown R.F., Vlahos C.J. Biochem. Biophys. Res. Commun. 186:1992;624
24. Foukas L.C., Daniele N., Ktori C., Anderson K.E., Jensen J., Shepherd P.R. J. Biol. Chem. 277:2002;37124
25. Bain J., McLauchlan H., Elliot M., Cohen P. Biochem. J. 371:2003;199